CalciMedica, Inc. (CALC)

CalciMedica's stock has been impacted by several events in the past six months. The discontinuation of the Phase 2 KOURAGE trial for acute kidney injury due to a safety concern caused the stock to plummet. The company received notification from Nasdaq for not meeting continued listing standards due to low market value and bid price. The company reported its third-quarter 2025 financial results on November 12, 2025, and its 2025 financial results (including Q4 2025) on March 3, 2026.

As a clinical-stage biopharmaceutical company with no commercially approved products and $0.00 revenue, CalciMedica does not experience traditional product demand seasonality. The company's financial performance is tied to clinical trial progress, regulatory milestones, and financing activities.

CalciMedica, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory, immunologic diseases, and conditions involving cellular damage. Their primary product candidate, Auxora, is a CRAC channel inhibitor in development for acute pancreatitis, asparaginase-induced pancreatic toxicity, acute kidney injury, and severe COVID-19 pneumonia. The company is also developing oral CRAC channel inhibitors and CM5480 for pulmonary arterial hypertension.

CalciMedica, Inc. is headquartered in La Jolla, California, United States. The company's operations are focused on drug development rather than widespread commercialization.

CalciMedica's brand reputation has been negatively impacted by the discontinuation of the Phase 2 KOURAGE trial due to safety concerns, leading to a stock price drop and negative news coverage. The Nasdaq listing compliance issues further contributed to negative sentiment and concerns about the company's financial stability.

CalciMedica, Inc. has a mix of institutional and individual owners. There are 37 institutional owners and shareholders holding a total of 3,655,018 shares. Major institutional shareholders include Deerfield Management Company, L.P., Soleus Capital Management, L.P., Aisling Capital Management LP, Vanguard Group Inc, Geode Capital Management, Llc, Renaissance Technologies Llc, Boothbay Fund Management, Llc, Envestnet Asset Management Inc, Meritage Portfolio Management and Stonehage Fleming Financial Services Holdings Ltd. Key individual shareholders include James E. Flynn, Fred A. Middleton, Christy L. Shaffer, Hansoo Michael Keyoung and Eric W. Roberts.